- You have no items in your shopping cart
- Continue Shopping
NOVOS is a new longevity company offering science-based and data-driven nutraceuticals and tests to address aging, backed by longevity scientists who studied aging at Harvard University, MIT, Salk Institute, University of Washington and other institutes. The company’s launch product, NOVOS Core, contains 12 science-based ingredients to slow down aging. NOVOS will also offer tests to measure biological age.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005250/en/
NOVOS Core is a patent-pending nutraceutical containing 12 science-based ingredients to slow down aging, formulated by top scientists who studied aging at Harvard, MIT, Salk and other institutes. (Photo: Business Wire)
"For decades people have been trying to live longer by taking antioxidants, herbs, vitamins and other supplements. None of these have been proven effective for lifespan. Antioxidants can sometimes even shorten lifespan," says Chris Mirabile, Founder of NOVOS.
The NOVOS team of PhDs and medical doctors harnessed recent discoveries in aging, including the important role of the epigenome and protein accumulation in the aging process, to identify 12 ingredients, detailed on its website NovosLabs.com, to address aging in a synergistic way.
"We created NOVOS because we believe the science is finally here supporting ingredients that slow down aging and improve longevity. Scientists learned more about aging in the last 10 years than in the 1,000 years prior, and no other supplement or pharmaceutical company has applied this knowledge to date," added Mirabile.
"New insights into the aging process and the publication of studies about substances that can extend lifespan enabled us to finally create a science-based supplement to address no less than 9 important mechanisms of aging," says Dr. Kris Verburgh, MD and Chief Scientific Officer.
"These 9 mechanisms of aging are important reasons why we age, such as mitochondrial dysfunction, epigenetic dysregulation, genomic instability, cellular senescence, protein accumulation, and altered intercellular communication. NOVOS identified 12 substances that can impact these aging mechanisms, and combined them in NOVOS Core, the foundational launch product. A combination of ingredients is important because each mechanism needs to be addressed in order to meaningfully impact aging," says Verburgh.
NOVOS’ Scientific Advisory Board consists of top scientists in the longevity field, such as Professor Dr. Joao Pedro Magalhaes, PhD, of the University of Liverpool, Dr. Pamela Maher, PhD, from the Salk Institute for Biological Studies and NOVOS works closely with longevity experts, like Professor Dr. Matt Kaeberlein, PhD, at the University of Washington.
"The NOVOS formulation is informed by science and is the current state-of-the-art in longevity supplements," says NOVOS scientific board member Professor Joao Pedro de Magalhaes.
The company was founded by Chris Mirabile, CEO, and Dr. Kris Verburgh, Chief Scientific Officer. Mirabile is a serial entrepreneur and technologist, with a passion for health and aging, fueled by, among other things, being diagnosed with a brain tumor as a teenager. Verburgh is a medical doctor and researcher, who since a young age has been fascinated by aging. He is a partner at a $100 million dollar investment fund that invests in new biotechnologies to address aging, like epigenetic and transcriptomic therapies.
NOVOS is the go-to resource for people across the world who want to live longer, providing advice and information to slow down their aging. NOVOS offers newsletters, ebooks and webinars to share new insights into longevity, supporting a community of people who want to live long, healthy and productive lives. NOVOS is also a Public Benefit Corporation and part of its profit goes to funding aging research.
The data-driven approach of NOVOS is not only reflected in its nutraceuticals. The company also offers tests that track biological age and health, for example with novel devices that painlessly draw blood at home without a physician or needles, or by using facial AI tests and epigenetic tests to determine your biological age.
"One important part of the future of health is the shift of healthcare from the physician’s office to the living room. People should be able to track their health from the comfort of their own home. NOVOS’ science-based longevity nutraceuticals, in combination with tests to track your aging and health is a powerful combination for living a longer, healthier life," says Dr. Verburgh.
NOVOS’ foundational product, NOVOS Core, is available for purchase today. The company is headquartered in New York, with a global presence of team members, scientists and investors across the US, Europe and Asia.
About NOVOS
NOVOS’ goal is to help people to live longer, healthier lives. NOVOS develops pioneering science-based products to impact the aging process, addressing 9 important hallmarks of aging. NOVOS offers biological tests to assess biological age and health of its customers, such as facial AI, epigenetic testing and blood tests. The company is a platform sharing the latest insights and information into the aging process, and uniting people in their quest to live longer, healthier, more youthful lives. NOVOS was founded in 2018 and launched in January 2021 and is headquartered in New York while its team is spread across the globe. NOVOS has an advisory board of esteemed aging scientists and discerns itself by its science-based, data-driven approach. NOVOS is available for purchase at www.novoslabs.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005250/en/
Contacts
Maxwell Gustafsson
NOVOS
Phone number: +1 646-593-7337
Email: press@novoslabs.com
At a basic level, all companies have the same purpose — only some excel at it.
(Bloomberg) — Former U.S. Treasury Secretary Lawrence Summers warned of the risk of a “spontaneous deflating of financial markets” that have been pumped up by retail buying and exuberant investors.Most Read from BloombergZero Taxes, Golf and Beach Houses Create a Crypto Island ParadiseCan Indoor Farms Reach Skyscraper Height?China Is Building the World’s Largest National Park SystemBoris Johnson’s Furious MPs Worry That His Next Misstep Could Be FatalThere is “a lot of euphoria,” Summers said a
Microsoft (NASDAQ: MSFT) shares closed 3.3% lower on Tuesday after the U.S. Department of Labor reported that producer price inflation hit a historic high in November, up 9.6% from a year ago. This news came on top of a reported 6.8% jump in consumer prices that came out yesterday — the fastest rate of price growth in 40 years. Reporting on Microsoft's price decline, Bloomberg drew a direct line from the inflation data to the weakness in Microsoft's stock price. Think about it this way: Right now, analysts who track Microsoft stock are forecasting that the company will grow its earnings by about 15% annually over the next five years.
The world of renewable energy was blindsided today by proposed rules for residential solar in California. Net metering is being changed, which isn't a surprise, but the rules may make it hard for anything but the most expensive rooftop solar projects to be economical. Bloom Energy (NYSE: BE), which makes fuel cells for commercial buildings, was also down as much as 7.2% today. States adjust how net metering and grid access works on a regular basis, but California is by far the largest solar and renewable energy market in the country, so it gets a vast majority of the attention.
Our call of the day from Stifel sees the Fed working toward a bubble of the century. Here's what happened before.
Shares of creativity software leader Adobe (NASDAQ: ADBE) were down by 7.6% as of 12:30 p.m. ET Tuesday. The culprit may have been JPMorgan Chase (NYSE: JPM) stock analyst Sterling Auty, who downgraded the stock to neutral and put a $680 one-year price target on it. Adobe and some of its software peers were hit by the prognosticator's view that there will be limited upside for them in 2022. For the record, though, after Tuesday morning's slide, a $680 price target still implies some 12% upside from where Adobe is now trading.
Investors are being reminded of several risk factors that need to be considered with this investment.
Is it time for the bears to finally come out of hibernation? Not so fast, says Goldman Sachs. Volatility has ruled the Street recently, leading some to conclude that those with a more pessimistic outlook had been vindicated, but the firm believes stocks can still climb higher. According to Goldman Sachs’ head of U.S. equity strategy, David Kostin, the S&P 500 could hit 5,100 by next year. This would reflect gains of 10% should the index ultimately reach this target. “If you’re looking for a good
Supreme Court won’t block N.Y. healthcare vaccine mandate, Apple is poised to become first $3 trillion company, MGM Resorts to sell Mirage hotel to Hard Rock, and other news to start your day.
Shares of cloud software companies Datadog (NASDAQ: DDOG), Zscaler (NASDAQ: ZS), and Cloudflare (NYSE: NET) were falling on Tuesday in another rough day for tech stocks. In a wide-ranging note at the bank, J.P. Morgan software analyst Sterling Auty made new calls across the sector.
Shares of Sunrun (NASDAQ: RUN) sank on Tuesday after a regulatory proposal threatened to slow the solar industry's growth. As of 3:25 p.m. ET, Sunrun's stock price was down more than 13%. A draft of proposed changes to California's Net Energy Metering Program could drastically increase costs for consumers and eliminate "tens of thousands of jobs." It "represents California politics at its worst and loses sight of what constituents want — innovation, control, and fast solutions — in favor of propping up failed and stodgy incumbents," Fenster said in a press release.
(Bloomberg) — The Biden administration is considering imposing tougher sanctions on China’s largest chipmaker, according to people familiar with the situation, building on an effort to limit the country’s access to advanced technology.Most Read from BloombergZero Taxes, Golf and Beach Houses Create a Crypto Island ParadiseCan Indoor Farms Reach Skyscraper Height?China Is Building the World’s Largest National Park SystemBoris Johnson’s Furious MPs Worry That His Next Misstep Could Be FatalThe Na
Shares of Alzamend Neuro (NASDAQ: ALZN) surged 28% on Tuesday, as investors bought in ahead of the biotech's upcoming clinical data release for its experimental Alzheimer's treatment. Alzamend is an early stage biopharmaceutical company focused on creating therapies for neurodegenerative diseases and psychiatric conditions. Its investigational oral treatment for dementia related to Alzheimer's, AL001, has been shown to prevent cognitive impairment in mice. Alzamend is currently conducting a phase 1 human clinical study to evaluate the safety and proper dosing for AL001 in a planned phase 2 trial.
Making progress in its push to facilitate the transition to a hydrogen economy, Plug Power (NASDAQ: PLUG) announced its entrance into a long-term supply and logistics agreement today. Investors, however, aren't impressed, considering details of the partnership are rather scant. As of 12:14 p.m. ET, shares of Plug Power are down 6.2%. While Plug Power initially made its hay by providing fuel cell systems, the company has articulated a long-term vision of diversifying its business by producing green hydrogen.
Ford Motor (ticker: F) stock has more than doubled this year, and its executive chair, William Clay Ford, Jr., just disclosed a large purchase of shares of the auto giant. Ford Motor stock has rocketed 128% so far this year through Tuesday’s close. Bill Ford, as the chairman is known, paid $8.5 million on Dec. 10 for 412,500 shares, a per-share average price of $20.62 each. According to a form he filed Tuesday with the Securities and Exchange Commission, Bill Ford bought the shares through a trust that now owns 4 million Ford shares.
The SPAC craze may have peaked with Trump's bizarre pitch for a right-wing media company.
A rally attempt is ailing with the Nasdaq breaking below the 50-day line with Microsoft, Google and Tesla at key levels. The Fed decision is on tap.
The Dow Jones fell as Microsoft slid. The Senate voted to raise the debt ceiling. Tesla stock short circuited on an Elon Musk move.
(Bloomberg) — While U.S. stocks fell Tuesday ahead of what’s expected to be a hawkish Federal Reserve policy meeting, one investor just bet $65 million on a quick market rebound. Most Read from BloombergZero Taxes, Golf and Beach Houses Create a Crypto Island ParadiseCan Indoor Farms Reach Skyscraper Height?China Is Building the World’s Largest National Park SystemBoris Johnson’s Furious MPs Worry That His Next Misstep Could Be FatalThe trade saw someone purchase roughly 20,000 call spreads tha
This CEO is betting big on Bitcoin. But he's not alone.